MENSHealthcare · Biotechnology

MENS Stock Forecast: Jyong Biotech Ltd. Price Predictions for 2026-2027

Last close, 11 Sept 2026

$1.99

−1.00% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 3 of 100 as at 12 Sept 2026 — in the weakest quartile.

Market cap

$151.3M

Ticker Nerd rank

3 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

−12.3%

−5.2%

YTD

−49.6%

−96.9%

From 52W high

−97.0%

From 52W low

+36.3%

$66

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

MENS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Jyong Biotech Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026

3 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size

Issuance

Revisions

Value

Volatility

Quality

Accruals

Growth

Momentum

Size (71): Smaller than most of the companies we track.

Momentum (5): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

MENS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MENS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MENS appears on the weeks it earns a place.

Performance

MENS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, Jyong Biotech Ltd. returned −96.9% against +17.5% for the S&P 500, dividends included.

MENS vs S&P 500, last 12 monthsTotal return, rebased to 100

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MENS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Jyong Biotech Ltd. (MENS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: —
Price / sales: —
Price / book: —
EV / EBITDA: −65.9×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: 18.8%
Return on assets: −12.0%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Jyong Biotech Ltd. (MENS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

Jyong Biotech Ltd. has a market value of $151.3M and an enterprise value of $165.1M.
Shares outstanding: 74.2M.
Jyong Biotech Ltd. employs 27 people.

market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

MENS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
MENSJyong Biotech Ltd.	$151.3M	3
CRBPCorbus Pharmaceuticals Holdings, Inc.	$150.4M	23
NRXPNRX Pharmaceuticals, Inc.	$142.6M	20
HUMAHumacyte, Inc.	$153.0M	17
LENZLENZ Therapeutics, Inc.	$141.4M	24
SPRBSpruce Biosciences, Inc.	$154.3M	27
UNCYUnicycive Therapeutics, Inc.	$141.2M	35

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Jyong Biotech Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest MENS news & analysis

Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow

GlobeNewsWire · 3 Sept 2026neutral

Jyong Biotech Ltd. announced its participation in a StockFan Virtual Investor Non-Deal Roadshow, with the company based in New Taipei City, Taiwan/San Francisco, CA. The announcement, made via GlobeNewswire on Sept. 03, 2026, informs investors of the company's upcoming participation in the virtual investor event.

Why it matters — MENS watchers would care because the roadshow gives them a scheduled opportunity to hear directly from Jyong Biotech management about the company's business.

FAQ

Frequently asked questions about MENS stock

How does Ticker Nerd's model rank MENS?

As at 12 Sept 2026, Jyong Biotech Ltd. ranks 3 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (71 of 100).

What is the MENS stock forecast for 2030?

No analyst covering Jyong Biotech Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MENS are extrapolating price history, which says nothing about the business.

How has MENS stock performed over the past year?

Jyong Biotech Ltd. returned -96.9% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Jyong Biotech Ltd. do?

Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases.

What is the latest news on MENS?

The most recent item we track (GlobeNewsWire, 3 Sept 2026): "Jyong Biotech Announces Participation in StockFan Virtual Investor Non-Deal Roadshow". Jyong Biotech Ltd. announced its participation in a StockFan Virtual Investor Non-Deal Roadshow, with the company based in New Taipei City, Taiwan/San Francisco, CA. The announcement, made via GlobeNewswire on Sept. 03, 2026, informs investors of the company's upcoming participation in the virtual investor event.

Company

About Jyong Biotech Ltd.

Jyong Biotech Ltd. is a Taiwan-based biotechnology company focused on developing and commercializing plant-derived medicines for urinary system diseases. Its current product pipeline includes candidate therapies for benign prostatic hyperplasia and lower urinary tract symptoms, prostate cancer, and interstitial cystitis or bladder pain syndrome. The company concentrates on botanical drug development, combining research and commercialization efforts around differentiated therapeutics designed for unmet medical needs. Jyong Biotech Ltd. operates with an initial commercial focus on the United States, the European Union, and Asia, including Taiwan and mainland China. As a specialized biopharmaceutical firm, it plays a role in advancing novel natural-origin treatments within the broader pharmaceuticals and biotechnology market.

CEO Ms. Fu-Feng Kuo · 27 employees · Taiwan · https://jyongbio.com